RT Journal Article SR Electronic T1 Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP 287 OP 294 DO 10.1183/09031936.00082909 VO 35 IS 2 A1 D. P. Tashkin A1 B. Celli A1 S. Kesten A1 T. Lystig A1 S. Mehra A1 M. Decramer YR 2010 UL http://erj.ersjournals.com/content/35/2/287.abstract AB UPLIFT (Understanding Potential Long-Term Improvements in Function with Tiotropium), a 4-yr trial of tiotropium in chronic obstructive pulmonary disease, allowed for assessment of smoking status on long-term responses to maintenance bronchodilator therapy. 5,993 patients were randomised (tiotropium/placebo). Lung function, St George's Respiratory Questionnaire, exacerbations and adverse events were followed. Patients were characterised as continuing smokers (CS), continuing ex-smokers (CE), or intermittent smokers (IS) based on self-reporting smoking behaviour. 60%, 14% and 26% of patients were CE, CS and IS, respectively. The rate of forced expiratory volume in 1 s (FEV1) decline for placebo patients was most rapid in CS (-51±4, -36±2 and -23±2 mL·yr−1 in CS, IS, and CE, respectively). Tiotropium did not alter FEV1 decline, but was associated with significant improvements in pre- and post-bronchodilator FEV1 over placebo that persisted throughout the 4-yr trial for each smoking status (pre-bronchodilator: 125, 55 and 97 mL at 48 months in CS, IS and CE, respectively; p≤0.0003). Tiotropium reduced exacerbation risk in CS (HR (95%CI) 0.81 (0.68–0.97)), in CE (0.86 (0.79–0.93)) and trended towards significance in IS (0.89 (0.80–1.01)). At 4 yrs, St George’s Respiratory Questionnaire for tiotropium patients improved the most in CS (-4.62 units, p = 0.0006) and the least in IS (-0.54 units, p = 0.55), compared with control. Tiotropium provided long-term benefits irrespective of smoking status, although differences among categories were observed.